文献速递呼吸危重症与机械通气呼吸道感染

免疫抑制患者接受ECMO治疗重度ARDS的六个月结局:国际多中心回顾性研究

Six-Month Outcome of Immunocompromised Patients with Severe Acute Respiratory Distress Syndrome Rescued by Extracorporeal Membrane Oxygenation. An International Multicenter Retrospective Study.
PubMed 文献 · Am J Respir Crit Care Med · 2018-01-01

该国际多中心回顾性研究纳入2008至2015年10个ICU中203例因重度ARDS接受ECMO的免疫抑制患者,发现6个月生存率仅30%,血液恶性肿瘤患者结局更差,免疫缺陷诊断至ECMO插管间隔少于30天与较低6个月死亡率相关。

要点

  • 免疫抑制患者ECMO治疗重度ARDS的6个月生存率仅30%。
  • 血液恶性肿瘤患者结局显著劣于其他免疫抑制患者(log-rank P=0.02)。
  • 免疫缺陷诊断至ECMO插管少于30天与较低6个月死亡率相关(OR 0.32)。

核心结论

  • 近期诊断的免疫缺陷与ECMO治疗重度ARDS患者更好的预后相关。
  • 该免疫抑制队列6个月生存率低,支持将ECMO限制于肿瘤/治疗预后现实、功能状态可接受且ECMO前死亡风险因素少的患者。

研究设计与样本

  • 回顾性多中心研究,纳入10个国际高ECMO病例量ICU。
  • 纳入2008至2015年203例免疫抑制合并重度ARDS接受ECMO的患者。
  • 免疫抑制定义为血液恶性肿瘤、活动性实体瘤、实体器官移植、获得性免疫缺陷综合征或长期/大剂量皮质类固醇或免疫抑制剂使用。

主要发现

  • 203例患者中位APACHE II评分28(25th-75th百分位20-33),年龄51(38-59)岁,ECMO前PaO2/FiO2 60(50-82)mm Hg。
  • 6个月生存率仅30%,中位ECMO时长8(5-14)天,ICU停留25(16-50)天。
  • 血液恶性肿瘤患者结局显著更差(log-rank P=0.02)。
  • ECMO相关大出血、套管感染和呼吸机相关性肺炎发生率分别为36%、10%和50%。
  • 多因素分析显示免疫缺陷诊断至ECMO插管少于30天与较低6个月死亡率相关(OR 0.32,95%CI 0.16-0.66;P=0.002)。

临床怎么用

  • 对免疫抑制合并重度ARDS患者考虑ECMO时,应评估免疫缺陷诊断时间、肿瘤/治疗预后、功能状态及ECMO前死亡风险因素。
  • 近期诊断免疫缺陷(<30天)的患者可能从ECMO获益更多。
  • 血液恶性肿瘤患者ECMO预后较差,需谨慎选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Because encouraging rates for hospital and long-term survival of immunocompromised patients in ICUs have been described, these patients are more likely to receive invasive therapies, like extracorporeal membrane oxygenation (ECMO).Objectives: To report outcomes of immunocompromised patients treated with ECMO for severe acute respiratory distress syndrome (ARDS) and to identify their pre-ECMO predictors of 6-month mortality and main ECMO-related complications.Methods: Retrospective multicenter study in 10 international ICUs with high volumes of ECMO cases. Immunocompromised patients, defined as having hematological malignancies, active solid tumor, solid-organ transplant, acquired immunodeficiency syndrome, or long-term or high-dose corticosteroid or immunosuppressant use, and severe ECMO-treated ARDS, from 2008 to 2015 were included.Measurements and Main Results: We collected demographics, clinical data, ECMO-related complications, and ICU- and 6 month-outcome data for 203 patients (median Acute Physiology and Chronic Health Evaluation II score, 28 [25th-75th percentile, 20-33]; age, 51 [38-59] yr; PaO2/FiO2, 60 [50-82] mm Hg before ECMO) who fulfilled our inclusion criteria. Six-month survival was only 30%, with a respective median ECMO duration and ICU stay of 8 (5-14) and 25 (16-50) days. Patients with hematological malignancies had significantly poorer outcomes than others (log-rank P = 0.02). ECMO-related major bleeding, cannula infection, and ventilator-associated pneumonia were frequent (36%, 10%, and 50%, respectively). Multivariate analyses retained fewer than 30 days between immunodeficiency diagnosis and ECMO cannulation as being associated with lower 6-month mortality (odds ratio, 0.32 [95% confidence interval, 0.16-0.66]; P = 0.002), and lower platelet count, higher Pco2, age, and driving pressure as independent pre-ECMO predictors of 6-month mortality.Conclusions: Recently diagnosed immunodeficiency is associated with a much better prognosis in ECMO-treated severe ARDS. However, low 6-month survival of our large cohort of immunocompromised patients supports restricting ECMO to patients with realistic oncological/therapeutic prognoses, acceptable functional status, and few pre-ECMO mortality-risk factors.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Schmidt M, Schellongowski P, Patroniti N, et al. Six-Month Outcome of Immunocompromised Patients with Severe Acute Respiratory Distress Syndrome Rescued by Extracorporeal Membrane Oxygenation. An International Multicenter Retrospective Study. Am J Respir Crit Care Med. 2018. PMID: 29298095. doi:10.1164/rccm.201708-1761OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。